Most Common Intoxication in Nephrology Ward Organophosphate Poisoning

Figures & data

Table 1. Clinical Manifestation of Organophosphate Poisoning in 42 Patients

Clinical manifestation	No	(%)
Nausea and Vomiting	19	(45.2%)
Salivation	14	(33.3%)
Bronchorrhea	12	(28.6%)
Dyspnea	11	(26.2%)
Abdominal pain	10	(23.8%)
Sweating	8	(19.0%)
Bradycardia	9	(21.4%)
Hypotension	8	(19.0%)
Fasciculation	7	(16.6%)
Coma	6	(14.3%)

Table 2. Clinical Variables in Respiratory Failure and Nonrespiratory Failure Patients

	Respiratory failure	Non‐respiratory failure	p
N	19	23
Age	54.3 ± 6.9	43.1 ± 5.6	p < 0.05
M/F	14/5	17/6	NS
Atropine (mg)	29.7 ± 14.5	9.1 ± 10.2	p < 0.05
Pralidoxime (g)	7.9 ± 4.6	5.3 ± 1.1	NS
Plasma cholinesterase (u/l)	116 ± 29	174 ± 51	NS
Plasma amyelase	436.1 ± 87.1	181.3 ± 29.6	p < 0.01
Hospitalization	12.1 ± 2.1	5.4 ± 1.9	p < 0.05
Fatality	1 (5%)	1 (4%)	NS

Figure 1. Factors associated with respiratory failure. As for nausea, salivation and bronchorrhea, they did not significantly differ in the prediction of respiratory failure. (Full color version available online.)

Figure 2. Factors associated with respiratory failure. Bradycardia (31.5%), hypotension (36.8%), fasciculation (36.8%) and coma (21.1%) were significant factors associated with respiratory failure. As for sweating, it did not significantly differ in the prediction of respiratory failure.

Table 3. Demographic and Laboratory Difference Between Oral Exposure and Nonoral Exposure in OP Poisoned Patients

	Oral exposure	Non‐oral exposure	p
N	33	9
Age	47.3 ± 9.7	48.6 ± 11.2	NS
M/F	25/8	6/3	NS
Atropine (mg)	23.6 ± 12.6	10.6 ± 6.4	p < 0.05
Pralidoxime(g)	9.6 ± 1.9	5.3 ± 1.4	p < 0.05
Plasma cholinesterase (u/l) (3000–9300)	147.3 ± 5.2	172.9 ± 43.5	NS
Hospitalization (days)	11.6 ± 3.9	6.4 ± 2.1	p < 0.05
Fatality	2	0	p < 0.05